NZ572856A - Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain - Google Patents

Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

Info

Publication number: NZ572856A
Authority: NZ; New Zealand
Prior art keywords: pain; compound; acid; treatment; disease
Prior art date: 2006-06-16

Application number

NZ572856A

Other languages

English (en)

Inventor

Benny Bang-Andersen

Andre Faldt

Tine Bryan Stensbol

Silke Miller

De Diego Heidi Lopez

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-16

Filing date

2007-06-15

Publication date

2012-02-24

2007-06-15 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2007-06-15 Priority claimed from PCT/DK2007/050076 external-priority patent/WO2007144006A1/en

2012-02-24 Publication of NZ572856A publication Critical patent/NZ572856A/en

Links

238000011282 treatment Methods 0.000 title claims abstract description 50
208000004296 neuralgia Diseases 0.000 title claims abstract description 26
208000021722 neuropathic pain Diseases 0.000 title claims abstract description 20
CVASBKDYSQKLSO-UHFFFAOYSA-N Tedatioxetine Chemical compound C1=CC(C)=CC=C1SC1=CC=CC=C1C1CCNCC1 CVASBKDYSQKLSO-UHFFFAOYSA-N 0.000 title claims description 7
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title abstract description 39
229940076279 serotonin Drugs 0.000 title abstract description 9
230000000966 norepinephrine reuptake Effects 0.000 title description 8
230000005764 inhibitory process Effects 0.000 title description 6
230000000697 serotonin reuptake Effects 0.000 title description 6
150000001875 compounds Chemical class 0.000 claims abstract description 163
150000003839 salts Chemical class 0.000 claims abstract description 84
238000000634 powder X-ray diffraction Methods 0.000 claims abstract 3
208000002193 Pain Diseases 0.000 claims description 81
230000036407 pain Effects 0.000 claims description 59
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
208000000094 Chronic Pain Diseases 0.000 claims description 21
201000010099 disease Diseases 0.000 claims description 17
208000019901 Anxiety disease Diseases 0.000 claims description 15
208000024714 major depressive disease Diseases 0.000 claims description 15
208000024827 Alzheimer disease Diseases 0.000 claims description 12
208000007848 Alcoholism Diseases 0.000 claims description 11
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 10
208000028698 Cognitive impairment Diseases 0.000 claims description 10
208000020401 Depressive disease Diseases 0.000 claims description 10
230000036506 anxiety Effects 0.000 claims description 10
208000010877 cognitive disease Diseases 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 10
201000003995 melancholia Diseases 0.000 claims description 10
201000001119 neuropathy Diseases 0.000 claims description 10
230000007823 neuropathy Effects 0.000 claims description 10
208000019906 panic disease Diseases 0.000 claims description 10
208000033808 peripheral neuropathy Diseases 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 10
208000011117 substance-related disease Diseases 0.000 claims description 10
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 9
208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 9
206010041250 Social phobia Diseases 0.000 claims description 9
208000024891 symptom Diseases 0.000 claims description 9
208000004454 Hyperalgesia Diseases 0.000 claims description 8
208000019022 Mood disease Diseases 0.000 claims description 8
206010012601 diabetes mellitus Diseases 0.000 claims description 8
230000036961 partial effect Effects 0.000 claims description 8
208000028173 post-traumatic stress disease Diseases 0.000 claims description 8
206010060800 Hot flush Diseases 0.000 claims description 7
208000035154 Hyperesthesia Diseases 0.000 claims description 7
208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 7
208000014674 injury Diseases 0.000 claims description 7
208000008035 Back Pain Diseases 0.000 claims description 6
208000032131 Diabetic Neuropathies Diseases 0.000 claims description 6
206010013654 Drug abuse Diseases 0.000 claims description 6
208000001640 Fibromyalgia Diseases 0.000 claims description 6
206010028980 Neoplasm Diseases 0.000 claims description 6
206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 6
206010047700 Vomiting Diseases 0.000 claims description 6
206010001584 alcohol abuse Diseases 0.000 claims description 6
208000025746 alcohol use disease Diseases 0.000 claims description 6
201000011510 cancer Diseases 0.000 claims description 6
208000003295 carpal tunnel syndrome Diseases 0.000 claims description 6
201000008482 osteoarthritis Diseases 0.000 claims description 6
206010044652 trigeminal neuralgia Diseases 0.000 claims description 6
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 5
208000008811 Agoraphobia Diseases 0.000 claims description 5
208000020925 Bipolar disease Diseases 0.000 claims description 5
208000030814 Eating disease Diseases 0.000 claims description 5
208000019454 Feeding and Eating disease Diseases 0.000 claims description 5
206010056465 Food craving Diseases 0.000 claims description 5
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 5
206010033664 Panic attack Diseases 0.000 claims description 5
208000018737 Parkinson disease Diseases 0.000 claims description 5
208000004983 Phantom Limb Diseases 0.000 claims description 5
206010034912 Phobia Diseases 0.000 claims description 5
201000009916 Postpartum depression Diseases 0.000 claims description 5
208000028017 Psychotic disease Diseases 0.000 claims description 5
206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 5
235000014632 disordered eating Nutrition 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
229960002715 nicotine Drugs 0.000 claims description 5
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
208000019899 phobic disease Diseases 0.000 claims description 5
206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
201000002859 sleep apnea Diseases 0.000 claims description 5
208000020431 spinal cord injury Diseases 0.000 claims description 5
206010064012 Central pain syndrome Diseases 0.000 claims description 4
206010065952 Hyperpathia Diseases 0.000 claims description 4
206010057852 Nicotine dependence Diseases 0.000 claims description 4
206010056238 Phantom pain Diseases 0.000 claims description 4
206010053552 allodynia Diseases 0.000 claims description 4
229940035676 analgesics Drugs 0.000 claims description 4
239000000730 antalgic agent Substances 0.000 claims description 4
230000000747 cardiac effect Effects 0.000 claims description 4
230000002980 postoperative effect Effects 0.000 claims description 4
201000009032 substance abuse Diseases 0.000 claims description 4
231100000736 substance abuse Toxicity 0.000 claims description 4
208000030507 AIDS Diseases 0.000 claims description 3
206010002383 Angina Pectoris Diseases 0.000 claims description 3
208000006820 Arthralgia Diseases 0.000 claims description 3
206010006002 Bone pain Diseases 0.000 claims description 3
208000001387 Causalgia Diseases 0.000 claims description 3
206010008479 Chest Pain Diseases 0.000 claims description 3
206010017076 Fracture Diseases 0.000 claims description 3
201000005569 Gout Diseases 0.000 claims description 3
206010019233 Headaches Diseases 0.000 claims description 3
208000008930 Low Back Pain Diseases 0.000 claims description 3
206010027452 Metastases to bone Diseases 0.000 claims description 3
208000019695 Migraine disease Diseases 0.000 claims description 3
208000029549 Muscle injury Diseases 0.000 claims description 3
206010029240 Neuritis Diseases 0.000 claims description 3
206010062501 Non-cardiac chest pain Diseases 0.000 claims description 3
206010030113 Oedema Diseases 0.000 claims description 3
208000001132 Osteoporosis Diseases 0.000 claims description 3
208000000450 Pelvic Pain Diseases 0.000 claims description 3
206010037779 Radiculopathy Diseases 0.000 claims description 3
208000010040 Sprains and Strains Diseases 0.000 claims description 3
206010043220 Temporomandibular joint syndrome Diseases 0.000 claims description 3
208000008548 Tension-Type Headache Diseases 0.000 claims description 3
210000000988 bone and bone Anatomy 0.000 claims description 3
208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims description 3
231100000869 headache Toxicity 0.000 claims description 3
230000005906 menstruation Effects 0.000 claims description 3
206010027599 migraine Diseases 0.000 claims description 3
230000009897 systematic effect Effects 0.000 claims description 3
206010048627 thoracic outlet syndrome Diseases 0.000 claims description 3
230000008733 trauma Effects 0.000 claims description 3
208000002551 irritable bowel syndrome Diseases 0.000 claims 1
239000002767 noradrenalin uptake inhibitor Substances 0.000 abstract description 3
229940127221 norepinephrine reuptake inhibitor Drugs 0.000 abstract description 3
239000003772 serotonin uptake inhibitor Substances 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 40
238000002474 experimental method Methods 0.000 description 28
239000002253 acid Substances 0.000 description 25
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 25
239000000523 sample Substances 0.000 description 25
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 23
238000002441 X-ray diffraction Methods 0.000 description 22
239000000243 solution Substances 0.000 description 22
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 20
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 20
239000000203 mixture Substances 0.000 description 20
229960004373 acetylcholine Drugs 0.000 description 19
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
235000019439 ethyl acetate Nutrition 0.000 description 17
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
239000002775 capsule Substances 0.000 description 15
229910001868 water Inorganic materials 0.000 description 15
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 14
230000000694 effects Effects 0.000 description 14
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 13
CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 13
241000700159 Rattus Species 0.000 description 13
JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 13
229960005261 aspartic acid Drugs 0.000 description 13
210000004027 cell Anatomy 0.000 description 13
239000011780 sodium chloride Substances 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
239000004480 active ingredient Substances 0.000 description 12
239000013078 crystal Substances 0.000 description 12
239000012071 phase Substances 0.000 description 12
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 11
210000004556 brain Anatomy 0.000 description 11
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 11
239000003826 tablet Substances 0.000 description 11
238000012360 testing method Methods 0.000 description 11
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 10
230000008485 antagonism Effects 0.000 description 10
239000005557 antagonist Substances 0.000 description 10
239000000872 buffer Substances 0.000 description 10
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
241001465754 Metazoa Species 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
238000001914 filtration Methods 0.000 description 9
239000012458 free base Substances 0.000 description 9
-1 glutamic acid monohydrate Chemical class 0.000 description 9
239000007924 injection Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
239000007788 liquid Substances 0.000 description 9
210000005036 nerve Anatomy 0.000 description 9
239000003921 oil Substances 0.000 description 9
239000000843 powder Substances 0.000 description 9
RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 8
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 8
208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 8
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
229960003638 dopamine Drugs 0.000 description 8
239000004220 glutamic acid Substances 0.000 description 8
235000013922 glutamic acid Nutrition 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
229960000448 lactic acid Drugs 0.000 description 8
238000000034 method Methods 0.000 description 8
238000001690 micro-dialysis Methods 0.000 description 8
235000019198 oils Nutrition 0.000 description 8
210000000287 oocyte Anatomy 0.000 description 8
239000012074 organic phase Substances 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
239000012453 solvate Substances 0.000 description 8
239000002904 solvent Substances 0.000 description 8
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 8
239000001361 adipic acid Substances 0.000 description 7
229960000250 adipic acid Drugs 0.000 description 7
235000011037 adipic acid Nutrition 0.000 description 7
208000035475 disorder Diseases 0.000 description 7
210000002442 prefrontal cortex Anatomy 0.000 description 7
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
239000001110 calcium chloride Substances 0.000 description 6
229910001628 calcium chloride Inorganic materials 0.000 description 6
235000011148 calcium chloride Nutrition 0.000 description 6
230000006378 damage Effects 0.000 description 6
238000004128 high performance liquid chromatography Methods 0.000 description 6
229910052757 nitrogen Inorganic materials 0.000 description 6
239000000047 product Substances 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 6
239000007787 solid Substances 0.000 description 6
238000001356 surgical procedure Methods 0.000 description 6
239000000725 suspension Substances 0.000 description 6
208000011580 syndromic disease Diseases 0.000 description 6
239000001828 Gelatine Substances 0.000 description 5
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
235000021314 Palmitic acid Nutrition 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000003042 antagnostic effect Effects 0.000 description 5
230000008859 change Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000000385 dialysis solution Substances 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
229910001629 magnesium chloride Inorganic materials 0.000 description 5
235000019359 magnesium stearate Nutrition 0.000 description 5
238000002156 mixing Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
230000004044 response Effects 0.000 description 5
230000007958 sleep Effects 0.000 description 5
210000005111 ventral hippocampus Anatomy 0.000 description 5
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 4
108060003345 Adrenergic Receptor Proteins 0.000 description 4
102000017910 Adrenergic receptor Human genes 0.000 description 4
241001631457 Cannula Species 0.000 description 4
241001269524 Dura Species 0.000 description 4
239000007995 HEPES buffer Substances 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
239000002585 base Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000009977 dual effect Effects 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
150000004677 hydrates Chemical class 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
229940116298 l- malic acid Drugs 0.000 description 4
229940049920 malate Drugs 0.000 description 4
235000011090 malic acid Nutrition 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
239000011550 stock solution Substances 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
OJVYWXLMPZJYGV-UHFFFAOYSA-N 4-[2-(4-methylphenyl)sulfanylphenyl]piperidine;hydrobromide Chemical compound Br.C1=CC(C)=CC=C1SC1=CC=CC=C1C1CCNCC1 OJVYWXLMPZJYGV-UHFFFAOYSA-N 0.000 description 3
102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 3
101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 3
108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229940123445 Tricyclic antidepressant Drugs 0.000 description 3
235000011054 acetic acid Nutrition 0.000 description 3
239000000654 additive Substances 0.000 description 3
OJYGBLRPYBAHRT-UHFFFAOYSA-N alphachloralose Chemical compound O1C(C(Cl)(Cl)Cl)OC2C(O)C(C(O)CO)OC21 OJYGBLRPYBAHRT-UHFFFAOYSA-N 0.000 description 3
229910000147 aluminium phosphate Inorganic materials 0.000 description 3
230000003502 anti-nociceptive effect Effects 0.000 description 3
239000000935 antidepressant agent Substances 0.000 description 3
229940005513 antidepressants Drugs 0.000 description 3
239000012131 assay buffer Substances 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000027455 binding Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
229960001231 choline Drugs 0.000 description 3
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
238000001816 cooling Methods 0.000 description 3
229960001270 d- tartaric acid Drugs 0.000 description 3
230000000994 depressogenic effect Effects 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000000835 electrochemical detection Methods 0.000 description 3
229940011871 estrogen Drugs 0.000 description 3
239000000262 estrogen Substances 0.000 description 3
230000000763 evoking effect Effects 0.000 description 3
230000005284 excitation Effects 0.000 description 3
235000013305 food Nutrition 0.000 description 3
210000002683 foot Anatomy 0.000 description 3
238000009472 formulation Methods 0.000 description 3
210000005153 frontal cortex Anatomy 0.000 description 3
239000001530 fumaric acid Substances 0.000 description 3
238000002825 functional assay Methods 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
230000007794 irritation Effects 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
239000006186 oral dosage form Substances 0.000 description 3
235000006408 oxalic acid Nutrition 0.000 description 3
239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 3
239000007921 spray Substances 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
238000004885 tandem mass spectrometry Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
239000003029 tricyclic antidepressant agent Substances 0.000 description 3
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
LBXRPPWPQUZKBO-DKWTVANSSA-N (2s)-2-aminobutanedioic acid;hydrate Chemical compound O.OC(=O)[C@@H](N)CC(O)=O LBXRPPWPQUZKBO-DKWTVANSSA-N 0.000 description 2
FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 2
XYGVIBXOJOOCFR-BTJKTKAUSA-N (z)-but-2-enedioic acid;8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine Chemical compound OC(=O)\C=C/C(O)=O.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F XYGVIBXOJOOCFR-BTJKTKAUSA-N 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
UGBLISDIHDMHJX-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one;hydrochloride Chemical compound [Cl-].COC1=CC=CC=C1N1CC[NH+](CCCC(=O)C=2C=CC(F)=CC=2)CC1 UGBLISDIHDMHJX-UHFFFAOYSA-N 0.000 description 2
CYUPFFKTTJMWLE-UHFFFAOYSA-N 1-bromo-2-(4-methylphenyl)sulfanylbenzene Chemical compound C1=CC(C)=CC=C1SC1=CC=CC=C1Br CYUPFFKTTJMWLE-UHFFFAOYSA-N 0.000 description 2
QZAYGJVTTNCVMB-PZFLKRBQSA-N 3-(2-amino-1,2-ditritioethyl)-1h-indol-5-ol Chemical compound C1=C(O)C=C2C(C([3H])C(N)[3H])=CNC2=C1 QZAYGJVTTNCVMB-PZFLKRBQSA-N 0.000 description 2
102000035037 5-HT3 receptors Human genes 0.000 description 2
108091005477 5-HT3 receptors Proteins 0.000 description 2
102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 2
101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 2
102100024954 5-hydroxytryptamine receptor 3A Human genes 0.000 description 2
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
108091006146 Channels Proteins 0.000 description 2
108010000659 Choline oxidase Proteins 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
101150104779 HTR2A gene Proteins 0.000 description 2
101000783617 Homo sapiens 5-hydroxytryptamine receptor 2A Proteins 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
239000012891 Ringer solution Substances 0.000 description 2
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
239000003522 acrylic cement Substances 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
239000008272 agar Substances 0.000 description 2
239000000556 agonist Substances 0.000 description 2
238000002266 amputation Methods 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 2
229960002430 atomoxetine Drugs 0.000 description 2
230000006399 behavior Effects 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
244000309464 bull Species 0.000 description 2
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
230000001149 cognitive effect Effects 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
235000019788 craving Nutrition 0.000 description 2
230000006735 deficit Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
229960004132 diethyl ether Drugs 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
LJZWZCRYSWYDAW-UHFFFAOYSA-N ethyl 4-[2-(4-methylphenyl)sulfanylphenyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1C1=CC=CC=C1SC1=CC=C(C)C=C1 LJZWZCRYSWYDAW-UHFFFAOYSA-N 0.000 description 2
YKCVAWMEHFTLKF-UHFFFAOYSA-N ethyl 4-hydroxy-4-[2-(4-methylphenyl)sulfanylphenyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1(O)C1=CC=CC=C1SC1=CC=C(C)C=C1 YKCVAWMEHFTLKF-UHFFFAOYSA-N 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
239000008187 granular material Substances 0.000 description 2
210000001320 hippocampus Anatomy 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
206010022437 insomnia Diseases 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000003902 lesion Effects 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
229960001785 mirtazapine Drugs 0.000 description 2
RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 2
238000002552 multiple reaction monitoring Methods 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
229960002748 norepinephrine Drugs 0.000 description 2
230000001473 noxious effect Effects 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
229960005343 ondansetron Drugs 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
230000008447 perception Effects 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000010992 reflux Methods 0.000 description 2
230000003252 repetitive effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
239000012047 saturated solution Substances 0.000 description 2
230000001624 sedative effect Effects 0.000 description 2
230000020341 sensory perception of pain Effects 0.000 description 2
239000002002 slurry Substances 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
238000011477 surgical intervention Methods 0.000 description 2
230000009747 swallowing Effects 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000020679 tap water Nutrition 0.000 description 2
239000008399 tap water Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
229960004688 venlafaxine Drugs 0.000 description 2
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
238000012795 verification Methods 0.000 description 2
238000005303 weighing Methods 0.000 description 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
OZDAOHVKBFBBMZ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)[C@@H](N)CCC(O)=O OZDAOHVKBFBBMZ-DFWYDOINSA-N 0.000 description 1
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
WQONPSCCEXUXTQ-UHFFFAOYSA-N 1,2-dibromobenzene Chemical compound BrC1=CC=CC=C1Br WQONPSCCEXUXTQ-UHFFFAOYSA-N 0.000 description 1
DFGQDTZCEYGOTO-UHFFFAOYSA-N 2-hydroxycyclodecan-1-one Chemical compound OC1CCCCCCCCC1=O DFGQDTZCEYGOTO-UHFFFAOYSA-N 0.000 description 1
BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 1
BSYNFGPFPYSTTM-UHFFFAOYSA-N 2-hydroxypropanoic acid;hydrate Chemical compound O.CC(O)C(O)=O BSYNFGPFPYSTTM-UHFFFAOYSA-N 0.000 description 1
FKHYYOUFMJBLAF-UHFFFAOYSA-N 3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)-n-methylpropan-1-amine Chemical compound S1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 FKHYYOUFMJBLAF-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
WLHCBQAPPJAULW-UHFFFAOYSA-N 4-methylbenzenethiol Chemical compound CC1=CC=C(S)C=C1 WLHCBQAPPJAULW-UHFFFAOYSA-N 0.000 description 1
102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000023584 Alzheimer disease 10 Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
231100000450 ECx Toxicity 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
239000001116 FEMA 4028 Substances 0.000 description 1
OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
101000761343 Homo sapiens 5-hydroxytryptamine receptor 3A Proteins 0.000 description 1
101150013372 Htr2c gene Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000001294 Nociceptive Pain Diseases 0.000 description 1
102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
QSVWKBUDZWXCAX-DKWTVANSSA-N O.O[C@@H](CC(O)=O)C(O)=O Chemical compound O.O[C@@H](CC(O)=O)C(O)=O QSVWKBUDZWXCAX-DKWTVANSSA-N 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004696 Poly ether ether ketone Substances 0.000 description 1
206010036105 Polyneuropathy Diseases 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000674 adrenergic antagonist Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
230000004075 alteration Effects 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000004596 appetite loss Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229960004853 betadex Drugs 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000008063 biphasic behavorial response Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Inorganic materials [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960001653 citalopram Drugs 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000019771 cognition Effects 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
229940125758 compound 15 Drugs 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000007797 corrosion Effects 0.000 description 1
238000005260 corrosion Methods 0.000 description 1
210000005080 cortical synaptosome Anatomy 0.000 description 1
238000003869 coulometry Methods 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000003479 dental cement Substances 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
230000009365 direct transmission Effects 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
238000009826 distribution Methods 0.000 description 1
210000005064 dopaminergic neuron Anatomy 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229960002866 duloxetine Drugs 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
LJMRGEJPNBDHOD-UHFFFAOYSA-N ethyl 4-[2-(4-methylphenyl)sulfanylphenyl]piperidine-1-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1CN(C(=O)OCC)CCC1C1=CC=CC=C1SC1=CC=C(C)C=C1 LJMRGEJPNBDHOD-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 description 1
229960000588 flunixin Drugs 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
238000002657 hormone replacement therapy Methods 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
238000002690 local anesthesia Methods 0.000 description 1
235000021266 loss of appetite Nutrition 0.000 description 1
208000019017 loss of appetite Diseases 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
201000005518 mononeuropathy Diseases 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
229960002362 neostigmine Drugs 0.000 description 1
LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
208000001797 obstructive sleep apnea Diseases 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
WLGDAKIJYPIYLR-UHFFFAOYSA-N octane-1-sulfonic acid Chemical compound CCCCCCCCS(O)(=O)=O WLGDAKIJYPIYLR-UHFFFAOYSA-N 0.000 description 1
QXFHPLPMTXEJPV-UHFFFAOYSA-N octane-1-sulfonic acid;sodium Chemical compound [Na].CCCCCCCCS(O)(=O)=O QXFHPLPMTXEJPV-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000000014 opioid analgesic Substances 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000037324 pain perception Effects 0.000 description 1
230000008533 pain sensitivity Effects 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
229940067631 phospholipid Drugs 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920002530 polyetherether ketone Polymers 0.000 description 1
230000007824 polyneuropathy Effects 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000036515 potency Effects 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000000376 reactant Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
239000013074 reference sample Substances 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
108010006590 serotonin 5 receptor Proteins 0.000 description 1
229960002073 sertraline Drugs 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
208000022925 sleep disturbance Diseases 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
229960005137 succinic acid Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
210000003568 synaptosome Anatomy 0.000 description 1
229950002139 talsupram Drugs 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
230000001457 vasomotor Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
208000009935 visceral pain Diseases 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/12—Glutaric acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)

NZ572856A 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain NZ572856A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US80500906P	2006-06-16	2006-06-16
DKPA200600816		2006-06-16
DKPA200700423		2007-03-20
PCT/DK2007/050076 WO2007144006A1 (en)	2006-06-16	2007-06-15	Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

Publications (1)

Publication Number	Publication Date
NZ572856A true NZ572856A (en)	2012-02-24

Family

ID=39722478

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ572856A NZ572856A (en)	2006-06-16	2007-06-15	Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

Country Status (15)

Country	Link
JP (1)	JP2014098017A (zh)
KR (1)	KR101472595B1 (zh)
AR (1)	AR061480A1 (zh)
AT (1)	ATE508115T1 (zh)
BR (1)	BRPI0712758A2 (zh)
CA (1)	CA2784304A1 (zh)
DE (1)	DE602007014372D1 (zh)
DK (1)	DK2044020T3 (zh)
MY (1)	MY150698A (zh)
NZ (1)	NZ572856A (zh)
PT (1)	PT2044020E (zh)
RS (1)	RS51687B (zh)
SI (1)	SI2044020T1 (zh)
TN (1)	TNSN08461A1 (zh)
TW (1)	TWI444365B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101972931B1 (ko)	2017-10-19	2019-04-26	재단법인대구경북과학기술원	풍선 타입 피질전도 측정장치 및 이의 제조방법
CN116930385B (zh) *	2023-08-08	2024-02-20	北京爱思益普生物科技股份有限公司	一种高盐浓度制剂中化合物浓度的测定方法
CN117305360B (zh) *	2023-09-15	2024-09-24	江南大学	一种哺乳动物细胞核转染液及其制备方法和在细胞核内递送的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA81749C2 (uk) *	2001-10-04	2008-02-11	Х. Луннбек А/С	Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
AU2007260356B2 (en) *	2006-06-16	2013-01-24	H. Lundbeck A/S	Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

2007
- 2007-06-15 CA CA2784304A patent/CA2784304A1/en not_active Abandoned
- 2007-06-15 DE DE602007014372T patent/DE602007014372D1/de active Active
- 2007-06-15 SI SI200730594T patent/SI2044020T1/sl unknown
- 2007-06-15 RS RS20110223A patent/RS51687B/sr unknown
- 2007-06-15 NZ NZ572856A patent/NZ572856A/en not_active IP Right Cessation
- 2007-06-15 AT AT07764496T patent/ATE508115T1/de active
- 2007-06-15 PT PT07764496T patent/PT2044020E/pt unknown
- 2007-06-15 MY MYPI20084894 patent/MY150698A/en unknown
- 2007-06-15 AR ARP070102640A patent/AR061480A1/es unknown
- 2007-06-15 DK DK07764496.1T patent/DK2044020T3/da active
- 2007-06-15 BR BRPI0712758-8A patent/BRPI0712758A2/pt not_active IP Right Cessation
- 2007-06-20 TW TW096121999A patent/TWI444365B/zh not_active IP Right Cessation
2008
- 2008-11-17 TN TNP2008000461A patent/TNSN08461A1/en unknown
- 2008-12-11 KR KR1020087030260A patent/KR101472595B1/ko not_active Expired - Fee Related
2014
- 2014-02-03 JP JP2014018411A patent/JP2014098017A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
KR20090018630A (ko)	2009-02-20
PT2044020E (pt)	2011-05-12
DK2044020T3 (da)	2011-08-15
CA2784304A1 (en)	2007-12-21
RS51687B (sr)	2011-10-31
DE602007014372D1 (de)	2011-06-16
MY150698A (en)	2014-02-28
KR101472595B1 (ko)	2014-12-15
SI2044020T1 (sl)	2011-06-30
TWI444365B (zh)	2014-07-11
AR061480A1 (es)	2008-08-27
TW200817329A (en)	2008-04-16
BRPI0712758A2 (pt)	2012-09-25
ATE508115T1 (de)	2011-05-15
JP2014098017A (ja)	2014-05-29
TNSN08461A1 (en)	2010-04-14

Publication	Publication Date	Title
CA2656057C (en)	2012-10-02	Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
EP2139479B1 (en)	2012-12-12	4-[2-(4-methylphenylsulfanyl)phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistent depression or residual symptoms in depression
US20140296290A1 (en)	2014-10-02	Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
NZ572856A (en)	2012-02-24	Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
CN101472891B (zh)	2013-08-21	有神经病痛治疗用血清素和去甲肾上腺素再摄取综合抑制作用的4-[2-(4-甲基苯硫基)苯基]哌啶的结晶形式
HK1134287B (zh)	2014-05-09	有神经病痛治疗用血清素和去甲肾上腺素再摄取综合抑制作用的4-[2-(4-甲基苯硫基)苯基]哌啶的结晶形式
HK1142007B (zh)	2013-02-08	有adhd，忧郁症，治疗抵抗的抑郁症或抑郁症的残留症状治疗用血清素和去甲肾上腺素再摄取综合抑制作用的4-[2-(4-甲基苯硫基)苯基]哌啶

Legal Events

Date	Code	Title	Description
2012-06-29	PSEA	Patent sealed
2014-05-30	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 JUN 2017 BY CPA GLOBAL Effective date: 20140501
2017-05-26	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUN 2018 BY CPA GLOBAL Effective date: 20170505
2018-12-21	LAPS	Patent lapsed